期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

新型肠道病毒71型全病毒灭活疫苗质量控制研究 被引量：3

Research on quality control of innovative inactivated enterovirus 71(EV71) whole-virus vaccine
原文传递
导出
摘要 近年来手足口病（HFMD）已成为西太平洋地区严重的公共卫生问题。2008年1月至2014年6月,我国大陆共报告HFMD 1 082万例,死亡3 036例[1]。研发疫苗是防控HFMD流行的有效措施。EV71为引起严重HFMD的主要病原体,国内外针对EV71开展多项疫苗研究,目前研发疫苗的类型包括全病毒灭活疫苗[2-4]、减毒活疫苗[5]、重组VLP疫苗[6-7]以及多肽疫苗[8-9]等, Enterovirus 71（EV71）vaccine is the innovative vaccine that was first developed in China.A series of studies on the quality control specification,standards and the evaluation methods for EV71 vaccine have been cooperatively carried out in multiple institutions to ensure high quality of the vaccine.This article is aimed to review and summarize the research progress of quality control of the inactivated whole-virus EV71 vaccine in China.
作者 高帆 姚昕 毛群颖 梁争论
机构地区 中国食品药品检定研究院
出处 《中国病毒病杂志》 CAS 2015年第2期85-89,共5页 Chinese Journal of Viral Diseases
基金 国家高技术研究发展计划(863计划)(2012AA02A402)
关键词 肠道病毒71型(EV71) 疫苗 质量控制 Enterovirus 71（EV71） Vaccine Quality control
分类号 R446.5 [医药卫生—诊断学]
  • 相关文献

参考文献31

  • 1中国疾病预防控制中心.法定传染病报告[EB/OL].(2013-03-27)[2013-10-12].http://www.chinacdc.cn/tjsj/fdcrbbg/.
  • 2Dong C, Wang J, Liu L, et al. Optimized development of a candidate strain of inactivated EV71 vaccine and analysis of its immunogenieity in rhesus monkeys [J]. Hum Vaccine, 2010, 6 (12): 1028-1037.
  • 3Liu L, Zhang Y, Wang J, et al. Study of the integrated im mune response induced by an inactivated EV71 vaccine [J]. PLoSOne, 2013, 8 (1): e54451.
  • 4Bek EJ, Hussain KM, Phuektes P, et al. Formalin inactiva ted vaccine provokes cross-protective immunity in a mouse model of human enterovirus 71 infection [J]. Vaccine, 2011, 29 (29/30); 4829-4838.
  • 5Arita M, Nagata N, Iwata N, et al. An attenuated strain of enterovirus 71 belonging to genotype a showed a broad spec- trum of antigenieity with attenuated neurovirulence in cyno molgusmonkeys[J].J Virol, 2007, 81 (17): 9386- 9395.
  • 6Sun S, Jiang L, Liang Z, et al. Evaluation of monovalent and bivalent vaccines against lethal Enterovirus 71 and Cox- saekievirus A16 infection in newborn mice [J]. Hum Vaecin Immunother, 2014:e29823.
  • 7Chung CY, Chen CY, Lin SY, etal. Enterovirus 71 virus like particle vaccine: improved production conditions for en- hanced yield [J]. Vaccine, 2010, 28 (43) :6951-6957.
  • 8Foo DG, Alonso S, Chow VT, et al. Passive protection a- gainst lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide [J]. Microbes Infect, 2007, 9 (11): 1299-1306.
  • 9Liu JN, Wang W, Duo JY, et al. Combined peptides of hu- man enterovirus 71 protect against virus infection in mice [J]. Vaccine, 2010, 28 (46) :7444-7451.
  • 10ClinicalTrials. gov. Safety and immunogenicity study of an inacti- vated vaccine against hand, foot and mouth disease caused by en- terovirus [EB/OL]. (2012-09) [2014 08-22]. http: //clini- caltrials, gov/ct2/show/NCT01376479.

二级参考文献41

  • 1金博,Richard Yan-Hui Wang,程留芳,裘奇,史维国.免疫佐剂对丙肝核酸疫苗免疫效果的影响[J].现代中西医结合杂志,2005,14(16):2103-2106. 被引量：4
  • 2Yeo WM, Chow VT. The VP1 structural protein of enterovirus 71 interacts with human ornithine decarboxylase and gene trap ankyrin repeat. Microb Pathog, 2007, 42 (4): 129-137.
  • 3Chen HL, Huang JY, Chu TW, et al. Expression of VPI protein in the milk of transgenic mice: a potential oral vaccine protects against enterovirus 71 infection. Vaccine, 2008, 26 (23): 2882- 2889.
  • 4Luo ST, Chiang PS, Chao AS, et al. Enterovirns 71 maternal antibodies in infants, Taiwan. Emerg Infect Dis, 2009, 15 (4):581- 584.
  • 5Iwai M, Masaki A, Hasegawa S, et al. Genetic changes of coxsackievirus A16 and enterovirus 71 isolated from hand, foot, and mouth disease patients in Toyama, Japan between 1981 and 2007. Jpn J Infect Dis, 2009, 62 (4): 254-259.
  • 6Zhu SB, Weng KZ, Zhou HW, et al. Severe enterovirus 71-associated hang-foot-and-mouth disease complicated by brainstem encephalitis: report of 2 cases. Chin J Contemporary Pediatrics, 2009, 11 (6): 502-503.
  • 7Li X, Mao C, Ma S, et al. Generation of neutralizing monoclonal antibodies against Enterovirus 71 using synthetic peptides. Biochem Biophys Res Commun, 2009, 390 (4): 1126-1128.
  • 8Wang SM, Liu CC. Enterovirus 71: epidemiology, pathogenesis and management. Expert Rev Anti Infect Ther, 2009, 7 (6): 735-742.
  • 9Ang LW, Koh BK, Chan KP, et al. Epidemiology and control of hand, foot and mouth disease in Singapore, 2001-2007. Ann Acad Med Singapore, 2009, 38 !2): 106-112.
  • 10Wu TC, Wang YF, Lee YP, et al. Immunity to avirulent enterovirus 71 and coxsackie A16 virus protects against enterovirus 71 infection in mice. J Virol, 2007,81(19):10310-10315.

共引文献46

同被引文献26

引证文献3

二级引证文献13

中国病毒病杂志
2015年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部